Kymera Therapeutics

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kymera Therapeutics reports successful 2022, eyes growth through strategic partnerships

Kymera Therapeutics had a successful year, with promising data in multiple programs and a focus on targeted protein degradation.
The company's financial position is strong, with key goals set for 2023, including collaborations and advancing pipeline programs.
Challenges lie in program prioritization, mechanism of action clarity, and optimizing dosing strategies, while opportunities exist in partnerships and therapeutic innovation.
Overall, Kymera's innovative approach and strategic outlook position it well for growth and continued success in 2023.

Kymera Therapeutics reports solid Q1 performance and eyes clinical milestones

Kymera Therapeutics is progressing well in its pipeline development, focusing on innovative programs with broad enrollment criteria.
Financially, the company is stable with a strong cash position and a clear runway into the future.
While facing challenges in capital allocation and program development, Kymera is actively seeking opportunities for growth and collaboration.

Kymera Therapeutics reports robust earnings, advances in clinical trials

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a patient-centric approach to drug development.
While facing challenges in clarity on certain trial aspects and partnership limitations, the company is well-positioned for growth and innovation.
Opportunities lie in expanding clinical studies, developing new INDs, and exploring additional indications for their drug portfolio.

Kymera Therapeutics achieves clinical milestones and financial stability for growth

Kymera Therapeutics has made significant progress in clinical development and financial stability, positioning the company for future growth and success.
The company's focus on genetically validated targets, degrader mechanisms, and combination therapies underscores a strategic and innovative approach to drug development.
While facing challenges in dose optimization and safety standards, Kymera has opportunities to leverage its strengths in solid tumors and immunology for therapeutic advancements.
Overall, Kymera's performance, strengths, and opportunities outweigh the challenges, indicating a promising outlook for the company's future in the biopharmaceutical industry.

Kymera Therapeutics reports robust earnings, advances oral immunology pipeline

Kymera Therapeutics is in a strong financial position with a clear runway for growth, focusing on advancing their oral immunology pipeline and strategic partnerships. They face challenges in prioritizing indications but have opportunities for collaborations and innovative therapeutic development.
The company's progress in clinical programs, including dose escalation trials and milestone achievements, reflects their commitment to advancing novel therapies and addressing unmet medical needs in inflammatory diseases, oncology, and immunology.

Kymera Therapeutics reports solid Q1 performance and eyes program expansion

Kymera Therapeutics had a strong start in 2024 with promising program updates and financial stability.
The company's focus on innovative degrader medicines and potential indication expansion positions it for future growth.
Challenges in data disclosure timing and partnership decisions require strategic navigation for sustained success.
Overall, Kymera's performance, strengths, and opportunities indicate a positive trajectory with key milestones ahead.

Kymera Therapeutics reports strong Q2 earnings and eyes CNS expansion

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a focus on innovative drug development approaches.
While facing challenges in market competition and financial management, the company is well-positioned to capitalize on growth opportunities.
Overall, Kymera's emphasis on developing effective oral immunology drugs and exploring CNS indications sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO and Jared Gollob, Chief Medical Officer of Kymera Therapeutics, will present at the Piper Sandler 32nd Annual Healthcare Conference being held virtually from December 1 to December 3, 2020.

Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference

WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the Stifel 2020 Virtual Healthcare Conference at 8:00 a.m. ET on Tuesday, November 17, 2020.

Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

Well positioned to advance a leading pipeline of targeted protein degradation medicines with recent completion of upsized initial public offering and strategic collaboration with Sanofi

Kymera Therapeutics Announces Third Quarter 2020 Financial Results and Provides Business Update

WATERTOWN, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader therapeutics, today announced the company will present new preclinical data for its IRAKIMiD and STAT3 degrader programs at the 62nd American Society of Hematology (ASH) Annual Meeting taking place virtually from Dec. 5-8, 2020.

Kymera Therapeutics to Present Data on Novel IRAKIMiD and STAT3 Protein Degraders at Virtual 62nd American Society of Hematology (ASH) Annual Meeting

Kymera reports positive data for RAK4 degrader, KT-474.

Kymera Reports Positive Data, And Other News: The Good, Bad And Ugly Of Biopharma

WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein Degradation Summit on Oct. 14 and 15. Kymera Co-Founder, President and CEO, Nello Mainolfi, PhD, will deliver a keynote presentation, “Targeted Protein Degradation Beyond Oncology,” and share recent data related to the company’s IRAK4 program including findings from the company’s non-interventional trial in hidradenitis suppurativa (HS) patients. Haojing Rong, PhD, Vice President of Pre-Clinical Development, will present on Kymera’s efforts to elucidate preclinical pharmacokinetic/pharmacodynamic relationships to predict clinical PK/PD.

Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit

Data to be presented at the 5 th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)

Kymera Therapeutics to Present Interim Results from a Non-Interventional Study Characterizing IRAK4 Expression and Demonstrating Proof of Mechanism of an IRAK4 Degrader in Patients with Hidradenitis Suppurativa

WATERTOWN, Mass., Sept.  14, 2020  (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced Nello Mainolfi, Co-Founder, President and CEO of Kymera Therapeutics, will present at the virtual Morgan Stanley 18th Annual Global Healthcare Conference at 5:00 p.m. ET on Wednesday, Sept. 16, 2020.

Kymera Therapeutics to Present at Morgan Stanley 18th Annual Global Healthcare Conference

WATERTOWN, Mass., Sept.  09, 2020  (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the appointments of Pamela Esposito, PhD, and Jeff Albers, JD, to its Board of Directors. Dr. Esposito is Chief Business Officer of Replimune, and Mr. Albers is President and Chief Executive Officer of Blueprint Medicines. Both join the Kymera Board with nearly two decades of biopharmaceutical leadership experience. 

Kymera Therapeutics Appoints Biopharma Veterans  Pamela Esposito and Jeff Albers to its Board of Directors

WATERTOWN, Mass., Aug.  27, 2020  (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the appointment of Richard Chesworth, PhD, to the role of Chief Scientific Officer. Dr. Chesworth brings more than twenty years of pharmaceutical and biotechnology industry experience to the Kymera executive team, and will oversee research, advancement of the pipeline to clinical development, including continued enhancements to the company’s proprietary Pegasus targeted protein degradation platform.

Kymera Therapeutics Appoints Dr. Richard Chesworth as Chief Scientific Officer

WATERTOWN, Mass., Aug.  25, 2020  (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the closing of its upsized initial public offering of 9,987,520 common shares, including the exercise in full by the underwriters of their option to purchase up to 1,302,720 additional shares of common stock, at a public offering price of $20.00 per share. The aggregate gross proceeds to Kymera from the offering, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by Kymera, were approximately $199.8 million.  All of the shares in the offering were sold by Kymera.

Kymera Therapeutics Announces Closing of Initial Public Offering with Exercise in Full of the Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Harmony Biosciences Holdings

Nano-X Imaging

U.S. IPO Weekly Recap: Biotechs And SPACs Ride The Summer Wave In A 4 IPO Week

WATERTOWN, Mass., Aug.  20, 2020  (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system, today announced the pricing of its upsized initial public offering of 8,684,800 common shares at a public offering price of $20.00 per share. All of the shares are being offered by Kymera. The gross proceeds of the offering, before deducting underwriting discounts and commissions, and other offering expenses payable by Kymera, are expected to be approximately $173.7 million. Kymera has granted the underwriters a 30-day option to purchase up to an additional 1,302,720 common shares at the initial public offering price.

News for Kymera Therapeutics Stock (KYMR)